Lars Johansson nominated as new Chairman of the Board of RLS Global AB
RLS Global AB announces today that Lars Johansson is nominated for election as new Chairman of the Board. Current Chairman Steve Krognes will step down and the change of Chairman is planned for an upcoming extraordinary general shareholder meeting.
Read moreRLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases
RLS Global AB (publ) (”RLS Global” or "the Company”) has completed a rights issue of shares that closed on 11 November, 2022. The rights issue is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") will be Wednesday, December 14th, 2022. The record date will…
Read moreRLS Global AB (publ) Interim Report, Q3, 2022
JULY 1st – SEPTEMBER 30th (Previous year in brackets) · Net sales amounted to TSEK 198 (TSEK 132). · Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2). · Earnings per share after dilution at SEK -0,07 (SEK 0,09). · Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6…
Read moreRLS Global: Outcome in RLS Global’s rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE…
Read morePresentation by Björn Larsson, CEO, RLS Global AB, about the company’s operations and the currently ongoing rights issue
Meet Björn Larsson, CEO of RLS Global AB, when he presents the company and the ongoing rights issue with a subscription period 28 October–11 November. The presentation was held at Redeye's latest investor event focusing on medtech on October 26.
Read moreRLS Global’s CEO Björn Larsson interviewed by Erik Penser Bank about the ongoing rights issue
Erik Penser Bank has today published a video-recorded interview with Björn Larsson, CEO, RLS Global AB. The reason for the CEO interview is to provide all shareholders and stakeholders with information in connection with RLS Global AB’s ongoing rights issue.
Read moreRLS Global: RLS Global publishes prospectus
RLS Global AB (publ) (”RLS Global” or the “Company”) today announces that the Swedish Financial Supervisory Authority (the “SFSA”, sw. Finansinspektionen) has approved the prospectus that RLS Global has prepared due to the upcoming rights issue. The prospectus is available at RLS Global’s website (www.rls.global) and Erik Penser Bank's website (www.penser.se).
Read moreRLS Global: RLS Global resolves on a fully guaranteed rights issue of approximately SEK 29.4 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE…
Read moreRLS Global carries out an issue of shares by way of set-off, totalling approximately SEK 10
The board of directors of RLS Global AB (publ) (the “Company” or “RLS Global”) has today, pursuant to the authorization granted by the annual general meeting on 19 May 2022, resolved on a directed issue of new shares, totalling approximately SEK 10 million (the “Issue”), to one of the Company’s principal shareholders, i.e., Zebra Holding…
Read moreRLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2022
APRIL 1[st] – JUNE 30[th ](Previous year in brackets) · Net sales amounted to TSEK 397 (TSEK 244). · Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5). · Earning per share before dilution at SEK -0,09 (SEK 0,13). · Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6…
Read moreBjörn Larsson new CEO of RLS Global
The Board of Directors of RLS Global AB (publ) has today appointed Björn Larsson as new CEO. Björn Larsson, who joins the company from Observe Medical ASA, will assume the role of CEO on 1 October.
Read moreNew case reports of ChloraSolv presented in Journal of Wound Care supplement
During the last six months, RLS Global and ConvaTec have worked in close collaboration to collect clinical experiences of ChloraSolv from three different wound centers in the UK. Six case studies have been compiled into a report and published as a supplement in Journal of Wound Care, issue no 7 2022 (https://www.magonlinelibrary.com/page/jowc/resources). The aim is to…
Read moreChloraSolv is available in the UK through NHS Supply Chain
As of 11[th] of July 2022, ChloraSolv is available in the UK to NHS (National Health Service) organizations who purchase from NHS Supply Chain or directly from ConvaTec. ChloraSolv is available to all NHS facilities who have an account at NHS Supply Chain. It is applicable to a range of settings, including hospitals as well as primary and…
Read moreRLS Global introduces ChloraSolv in the veterinary care segment in Scandinavia
RLS Global’s strategic focus is to expand its technical platform, buffered hypochlorite technology, to new indications, applications and geographical areas. Today, RLS Global can announce a strategic partnership with Swevet in the animal care segment for Sweden, Norway and Denmark.
Read moreRLS Global increases its presence in the Middle East
RLS Global strengthens its presence in the Middle East. Through a regional agent, Med Surg, the company will establish a local distribution network in Egypt, Saudi Arabia, Iraq, Lebanon, Qatar, the United Arab Emirates, Oman and Jordan.
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2022
JAN 1[st] – MARCH 31[st ](Previous year in brackets) · Net sales amounted to TSEK 305 (TSEK 50). · Earnings before interest and taxes (EBIT) amounted to TSEK -5 363 (TSEK -6 263). Earning per share before dilution at SEK -0,07 (SEK -0,09). · Cash flow from operating activities amounted to TSEK -6 730 (TSEK…
Read moreRLS Global announces management change
Karin Fischer has given notice that she intends to resign as CEO of RLS Global AB (publ). The Board has initiated the search for a new, R&D-focused CEO and Karin Fischer will continue in her role, until a new CEO has been appointed, to ensure a smooth succession.
Read moreRLS GLOBAL AB (publ) YEAR-END REPORT, Q4, 2021
OCTOBER 1[st ]– DECEMBER 31[st] (previous year in brackets) · Net sales amounted to TSEK 219 (TSEK 139) · Earnings before interest and taxes (EBIT) amounted to TSEK -7 478 (TSEK -7 655) · Earning per share before dilution at SEK -0,11 (SEK -0,12) · Cash flow from operating activities amounted to TSEK -4 887 (TSEK…
Read moreFurther progress with ChloraSolv[®] roll out across Europe – market access activities in the Netherlands signal positive momentum
RLS Global, a medical healthcare company based in Sweden, and ConvaTec, one of the world’s leading advanced wound care companies, have made continued progress with the distribution and commercialisation of ChloraSolv[®], a ground-breaking gentle wound debrider, in Europe.
Read moreRLS Global AB secures financing of SEK 20 million
RLS Global has today signed a credit facility, on market terms, of SEK 20 million to create flexible financing for the company’s continued growth. It is one of the company’s major shareholders that has provided this credit facility.
Read moreRLS Global AB (publ) Interim Report, Q3, 2021
JULY 1st – SEPTEMBER 3Oth · Net sales amounted to TSEK 132 (TSEK 793) · Earnings before interest and taxes (EBIT) amounted to MSEK -6,2 (MSEK -5,6) · Earning per share before dilution at SEK -0,09 (SEK-0,08) · Cash flow from operating activities amounted to MSEK 8,6 (MSEK-4,2) · Liquid assets at the end of…
Read moreRLS Global AB provides livestream strategy update focusing on the global collaboration with ConvaTec Ltd
RLS long term vision is to be a leading research driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as burns and dermatology. In order to maximize our patient reach, RLS intends to work with partners to commercialize its products globally.…
Read moreChloraSolv is regulatory approved for diabetic foot ulcers in New Zealand
RLS Global has received regulatory approval for ChloraSolv for treatment of diabetic foot ulcers in New Zealand. With this approval, RLS has established a first market presence in Oceania. The next step will be to broaden the indication in this market.
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q2, 2021
APRIL 1[st] – JUNE 3O[th] · Net sales amounted to TSEK 244 (TSEK 739) · Earnings before interest and taxes (EBIT) amounted to MSEK 8,5 (MSEK -5,6) · Other income TSEK 15 429 (TSEK 281) · Earning per share before dilution at SEK SEK 0,13 (SEK-0,09) · Cash flow from operating activities amounted to MSEK…
Read moreRLS Global AB and ConvaTec Ltd sign agreement on global commercial rights for ChloraSolv, an innovative wound debrider indicated for hard-to-heal wounds
RLS Global, a medical healthcare company based in Sweden and ConvaTec, one of the world’s leading companies in advanced wound care, have entered a global collaboration to commercialize ChloraSolv. ChloraSolv is a ground-breaking gentle debrider, which is already currently sold in some European countries. ChloraSolv will be included in ConvaTec’s Wound Hygiene[TM] Protocol of care…
Read moreRLS Global clinical study, ChloraSolv01, published in the Journal of Wound Care
RLS Global is pleased to announce that the outcome of the completed clinical study ChloraSolv01 is published today in the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds.
Read moreChloraSolv is regulatory approved in Kuwait for diabetic foot ulcers
RLS Global AB has received regulatory approval for ChloraSolv regarding the treatment of diabetic foot ulcers in Kuwait. With this approval, RLS has established the first market presence in the Middle East, which is an important region for RLS. The prevalence of diabetes in the Middle East is very high and is expected to increase…
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2021
JAN 1[st] – MARCH 31[st] · Net sales amounted to KSEK 50 (KSEK 374) · Earnings before interest and taxes (EBIT) amounted to MSEK -6,3 (MSEK -3,9) · Earning per share before dilution at SEK -0,09 (SEK-0,06) · Cash flow from operating activities amounted to MSEK -5,8 (MSEK-4,2) · Liquid assets at the end of…
Read moreChloraSolv is approved for leg ulcers – doubles the potential market size in Europe
RLS Global, whose ambition is to be a leading research-driven platform company for wounds, has received regulatory approval that ChloraSolv can also be used for leg ulcers. This increases the potential market size by 100 percent. ChloraSolv has been approved for diabetic foot ulcers since 2019, where now leg ulcers also are included.
Read moreRLS GLOBAL AB (publ) YEAR-END REPORT 2020
OCTOBER 1[st]–DECEMBER 31[st] · Net sales amounted to KSEK 139 (KSEK 54) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,2 (MSEK -8,9) · Earning per share before dilution at SEK -0,11 (SEK -0,15) · Cash flow from operating activities amounted to MSEK -7,0 (MSEK -5,7) · Liquid assets at the end of…
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q3, 2020
JULY 1[st] - SEPTEMBER 30[th] · Net sales amounted to KSEK 793 (KSEK 245) · Earnings before interest and taxes (EBIT) amounted to MSEK -5,6 (MSEK -6,2) · Earning per share before dilution at SEK -0,08 (SEK-0,11) · Cash flow from operating activities amounted to MSEK -4,2 (MSEK-7,4) · Liquid assets at the end of…
Read moreRLS Global presents positive results from the ChloraSolv01 study at the leading European Wound Management Conference, EWMA 2020
RLS Global is pleased to announce that an abstract has been reviewed by the EWMA Scientific Committee and accepted for Oral Presentation at the EWMA 2020 Virtual Conference. The abstract “ID no. 927” will be presented by Senior consultant, Associate professor Jan Apelqvist, Skåne University Hospital, Sweden.
Read moreChloraSolv is awarded by Region Skåne
RLS Global is pleased to inform about the acceptance of ChloraSolv by Region Skåne. ChloraSolv is available as of today, September 29[th]. This is the result of positive clinical evaluations from both acute- and primary care and it is an important milestone for RLS as Region Skåne is one of the largest regions in Sweden…
Read moreRLS Global presents data about ChloraSolv and its rapid response and high efficacy on biofilm
At the EWMA (European Wound Management Association) Conference in November, RLS will present data where our technology has been evaluated in an ex-vivo wound model with very exciting results on biofilm. The evaluation was carried out together with RISE, Research Institute of Sweden.
Read moreRLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2020
APRIL 1[st] - JUNE 30[th] · Net sales amounted to TSEK 739 (TSEK 464) · Earnings before interest and taxes (EBIT) amounted to MSEK -5,6 (MSEK -5,8) · Earnings per share before dilution at SEK -0,09 (SEK-0,02) · Cash flow from operating activities amounted to MSEK -5,5 (MSEK-6,3) · Liquid assets at the end of…
Read moreRLS clinical trial - ChloraSolv01 – is completed and the result is to be analyzed
RLS Global is pleased to announce that the database for ChloraSolv01 is closed and RLS has received the first statistical report and results. ChloraSolv01 is a pilot study in which the patient with chronic ulcers on the lower leg or foot is treated with ChloraSolv for five weeks. The study endpoints include for example the…
Read moreRLS Global AB has signed an agreement with Region Stockholm and Gotland for ChloraSolv®
RLS Global AB is pleased to inform that ChloraSolv is awarded on the current tender agreement in Region Stockholm and Gotland. The agreement is effective August 15[th], 2020. The clinical evaluation has been very positive and ChloraSolv is now available to all healthcare providers in the region such as inpatient- and outpatient care, primary care,…
Read moreIncreased interest in CariSolv due to the Corona pandemic
One consequence of the Corona pandemic is that the dental industry is facing a major shift in terms of caries treatment. Traditional treatment of caries attacks is done with drilling and repair. In connection with drilling in the tooth, aerosol is formed which radically increases the spread of infection during treatment. The dental industry is…
Read moreRLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2020
JANUARY 1[st] - MARCH 31[st] · Net sales amounted to TSEK 374 (260 TSEK) · The operating loss for the period was MSEK -3.9 (-5.7 MSEK) · Earnings per share after dilution at SEK -0.06 (-0.04) · Cash flow from operating activities amounted to MSEK -4.2 (-5.5 MSEK) · Equity ratio was 92 percent (84…
Read moreRLS Global (publ) change Certified Adviser to Redeye AB
RLS Global AB announces today that the company will change Certified Adviser from Erik Penser Bank to Redeye AB. The transition will take place as of April 1[st], 2020. The background is that RLS will gather all advice with Redeye AB.
Read moreChloraSolv is awarded on wound care tender in Region Kalmar Country Council and its municipalities
During the fall of 2019, RLS Global has worked intensively on the Swedish market with the aim to establish ChloraSolv as a product in the Swedish regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market (municipalities and regions) where OneMed has agreements. As RLS has communicated in the past,…
Read moreRLS Global continues to develop its Wound Care business area and sells off the dental care portfolio
RLS Global’s strategy is to ensure a strong market penetration for ChloraSolv together with regional/global partnerships. ChloraSolv is based on a unique buffered hypochlorite technology with documented clinical results within Advanced Wound Care. During 2020, RLS will initiate pre-clinical activities with the aim of broadening the product portfolio within new clinical areas. New clinical indications…
Read moreRLS Global AB (publ) Year-end Report, 2019
October 1st - December 31st • Net sales amounted to kSEK 54 (1,131) • The operating loss for the period was MSEK -8.9 (-5.9) • Earnings per share after dilution at SEK -0.15 (-0.10) • Cash flow from operating activities amounted to MSEK -5.7 (-5.0) • Cash and cash equivalents amounted to MSEK 41.8 (22.6)
Read moreAll patients enrolled for ChloraSolv01
RLS Global is pleased to announce that all patients are included in the study ChloraSolv 01, which has been performed on nine sites in Sweden. The inclusion criteria for the study are chronic wounds below the knee. The aim with the study is to obtain clinical data to regulatory extend the indication for use (diabetic…
Read moreRLS Global AB received its first order of ChloraSolv for clinical use
During the autumn of 2019, RLS Global focused on the Swedish market with the aim to get ChloraSolv established as a standard product in the regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market in municipalities and regions there OneMed has supplier agreements. RLS Global also has ongoing dialogue with international players…
Read moreRLS GLOBAL AB (PUBL) Interim Report, January - September, 2019
July 1st - September 30th · Net sales amounted to SEK 0.2 million (1.0) · Earnings before interest and taxes (EBIT) amounted to SEK -6,1 million (-4,9) · Earnings per share before dilution at SEK -0,11 (-0,08) · Cash flow from operating activities amounted to SEK -7,4 million (-5,8) · Liquid assets at the end…
Read moreThe new Shareholder list at RLS Global AB
RLS Global AB completed a directed new share issue raising proceeds of SEK 50 million as of 25th of September. It is very encouraging that RLS has engaged national- and international institutions to establish a long-term foundation for the company, says Karin Fischer, CEO RLS Global. The new shareholder list can be found at RLS…
Read moreRLS Global completes a directed new share issue of 7,520,000 shares, raising proceeds of SEK 50 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR…
Read moreRLS Global announces intention of a directed new share issue of shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR…
Read moreRLS Global signs agreement with OneMed AB
OneMed is one of the Nordic Countries largest distributors within medical technology providing services, support systems and products to the healthcare sector. RLS Global AB has signed a cooperation agreement with OneMed AB who will act as a distributor for ChloraSolv to address the municipalities and county councils with whom they have agreements with for…
Read moreAbout RLS Global
RLS Global is a Swedish MedTech company based in Gothenburg, founded in 1996. Through our advanced and unique Buffered Hypochlorite based Technology Platform we focus on developing products based on Gentle methods for Minimally Invasive Treatment.
Visit us
RLS Global AB
Neongatan 5
SE 431 53 Mölndal
Sweden
Contacts
Customer Services & Orders:
+46 31 780 68 20
customer@rlsglobal.com
Office
+46 31 780 68 20
customer@rlsglobal.com
